Millipore Sigma Vibrant Logo
Atención: Nos hemos mudado. Los productos Merck Millipore ya no pueden adquirirse en MerckMillipore.comMás información

119150 Adenosine A2A Receptor Antagonist II, SCH-58261 - CAS 160098-96-4 - Calbiochem

Ficha de datos de seguridad (MSDS o SDS), certificado de análisis y de calidad (CoA y CoQ), expedientes, folletos y otros documentos disponibles.

Sinónimos: 2-(furan-2-yl)-7-phenethyl-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine, SCH58261, SCH 58261

119150
Purchase on Sigma-Aldrich

Descripción

Replacement Information

Products

Número de referenciaEmbalaje Cant./Env.
119150-10MG Frasco de vidrio 10 mg
Description
OverviewA highly potent and selective antagonist of adenosine A2A receptor (Ki = 600 pM). Does not affect the activity of other adenosine receptors in any significant manner (Ki = 287 nM; 5.0 µM, and > 10 µM for A1, A2B, and A3 receptors, respectively). Displays neuroprotective effects in cerebral ischaemia in rats, and shown to counteract Parkinsonian-like muscle rigidity in rats.
Catalogue Number119150
Brand Family Calbiochem®
Synonyms2-(furan-2-yl)-7-phenethyl-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine, SCH58261, SCH 58261
References
ReferencesOngini, E., et al. 1999. Naunyn Schmiedebergs Arch. Pharmacol. 359, 7.
Monopoli, A., et al. 1998. Neuroport. 9, 3955.
Zocchi, C., et al. 1996. J. Pharmacol. Exp. Ther. 276, 398.
Popoli, P., et al. 2000. Neuropsychopharmacology. 22, 522.
Product Information
CAS number160098-96-4
FormOff-white solid
Hill FormulaC₁₈H₁₅N₇O
Chemical formulaC₁₈H₁₅N₇O
ReversibleY
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Primary TargetA2A Receptor
Primary Target K<sub>i</sub>600 pM
Purity≥99% by HPLC
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
Toxicity Standard Handling
Storage +2°C to +8°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C. Stock solutions are stable for up to 3 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications

Documentation

Adenosine A2A Receptor Antagonist II, SCH-58261 - CAS 160098-96-4 - Calbiochem Certificados de análisis

CargoNúmero de lote
119150

Referencias bibliográficas

Visión general referencias
Ongini, E., et al. 1999. Naunyn Schmiedebergs Arch. Pharmacol. 359, 7.
Monopoli, A., et al. 1998. Neuroport. 9, 3955.
Zocchi, C., et al. 1996. J. Pharmacol. Exp. Ther. 276, 398.
Popoli, P., et al. 2000. Neuropsychopharmacology. 22, 522.
Ficha técnica

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision31-May-2013 JSW
Synonyms2-(furan-2-yl)-7-phenethyl-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine, SCH58261, SCH 58261
DescriptionA highly potent and selective antagonist of adenosine A2A receptor (Ki = 600 pM). Does not affect the activity of other adenosine receptors in any significant manner (Ki = 287 nM; 5.0 µM, and > 10 µM for A1, A2B, and A3 receptors, respectively). Displays neuroprotective effects in cerebral ischaemia in rats, and shown to counteract Parkinsonian-like muscle rigidity in rats.
FormOff-white solid
Intert gas (Yes/No) Packaged under inert gas
CAS number160098-96-4
Chemical formulaC₁₈H₁₅N₇O
Structure formulaStructure formula
Purity≥99% by HPLC
Solubility100 mM in DMSO
Storage Protect from light
+2°C to +8°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C. Stock solutions are stable for up to 3 months at -20°C.
Toxicity Standard Handling
ReferencesOngini, E., et al. 1999. Naunyn Schmiedebergs Arch. Pharmacol. 359, 7.
Monopoli, A., et al. 1998. Neuroport. 9, 3955.
Zocchi, C., et al. 1996. J. Pharmacol. Exp. Ther. 276, 398.
Popoli, P., et al. 2000. Neuropsychopharmacology. 22, 522.